A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia

C. Michel Zwaan; Stefan Söderhäll; Benoit Brethon; Matteo Luciani; Carmelo Rizzari; Ronald W. Stam; Emmanuelle Besse; Catherine Dutreix; Franca Fagioli; Phoenix A. Ho; Carlo Dufour; Rob Pieters

doi:10.1111/bjh.15593

A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia

C. Michel Zwaan
, Stefan Söderhäll
, Benoit Brethon
, Matteo Luciani
, Carmelo Rizzari
, Ronald W. Stam
, Emmanuelle Besse
, Catherine Dutreix
, Franca Fagioli
, Phoenix A. Ho
, Carlo Dufour
, Rob Pieters

Onderzoeksoutput: Bijdrage aan tijdschrift › Brief › peer review

34 Citaten (Scopus)

Originele taal-2	Engels
Pagina's (van-tot)	623-627
Aantal pagina's	5
Tijdschrift	British journal of haematology
Volume	185
Nummer van het tijdschrift	3
DOI's	https://doi.org/10.1111/bjh.15593
Status	Gepubliceerd - mei 2019

Toegang tot document

10.1111/bjh.15593

Citeer dit

@article{d8deea6978934d10bdb4e5aefb54b5aa,

title = "A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia",

keywords = "FLT3, acute leukaemia, midostaurin, paediatric, relapsed/refractory",

author = "Zwaan, \{C. Michel\} and Stefan S{\"o}derh{\"a}ll and Benoit Brethon and Matteo Luciani and Carmelo Rizzari and Stam, \{Ronald W.\} and Emmanuelle Besse and Catherine Dutreix and Franca Fagioli and Ho, \{Phoenix A.\} and Carlo Dufour and Rob Pieters",

note = "Funding Information: This study was supported by funding from Novartis Pharmaceuticals Corporation. We thank the patients enrolled in this trial and their families for their participation. We also acknowledge all of the investigators at the study sites that participated in the trial: Erasmus MC–Sophia Children's Hospital, Rotterdam, the Netherlands; Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; H{\^o}pital Universitaire Robert-Debr{\'e}, Paris, France; IRCCS Ospedale Pediatrico Bambino Ges{\`u}, Rome, Italy; Fondazione MBBM, Azienda Ospedaliera San Gerardo, Monza, Italy; Paediatric Onco-Haematology, Stem Cell Transplantation and Cellular Therapy Division, A.O.U. Citt{\`a} della Salute e della Scienza di Torino, Ospedale Infantile Regina Margherita, Torino, Italy; Seattle Children's Hospital, Seattle, WA; Haematology Unit, IRCCS Instituto Giannina Gaslini, Genova, Italy; and Princess M{\'a}xima Centre for Paediatric Oncology, Utrecht, the Netherlands. We would also like to thank Katherine Mills-Luj{\'a}n, PhD, CMPP, Amarallys Cintron, PhD, and Pamela Tuttle, PhD, CMPP, of ArticulateScience LLC for medical editorial assistance with this manuscript, which was funded by Novartis Pharmaceuticals Corporation. Funding Information: This study was supported by funding from Novartis Pharmaceuticals Corporation. We thank the patients enrolled in this trial and their families for their participation. We also acknowledge all of the investigators at the study sites that participated in the trial: Erasmus MC–Sophia Children{\textquoteright}s Hospital, Rotterdam, the Netherlands; Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; H{\^o}pital Universitaire Robert-Debr{\'e}, Paris, France; IRCCS Ospedale Pediatrico Bambino Ges{\`u}, Rome, Italy; Fondazione MBBM, Azienda Ospedaliera San Gerardo, Monza, Italy; Paediatric Onco-Haematology, Stem Cell Transplantation and Cellular Therapy Division, A.O.U. Citt{\`a}della Salute e della Scienza di Torino, Ospedale Infantile Regina Margherita, Torino, Italy; Seattle Children{\textquoteright}s Hospital, Seattle, WA; Haematology Unit, IRCCS Instituto Giannina Gaslini, Genova, Italy; and Princess M{\'a}xima Centre for Paediatric Oncology, Utrecht, the Netherlands. We would also like to thank Katherine Mills-Luj{\'a}n, PhD, CMPP, Amarallys Cintron, PhD, and Pamela Tuttle, PhD, CMPP, of ArticulateScience LLC for medical editorial assistance with this manuscript, which was funded by Novartis Pharmaceuticals Corporation.",

year = "2019",

month = may,

doi = "10.1111/bjh.15593",

language = "English",

volume = "185",

pages = "623--627",

journal = "British journal of haematology",

issn = "0007-1048",

publisher = "John Wiley and Sons Inc.",

number = "3",

}

TY - JOUR

T1 - A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia

AU - Zwaan, C. Michel

AU - Söderhäll, Stefan

AU - Brethon, Benoit

AU - Luciani, Matteo

AU - Rizzari, Carmelo

AU - Stam, Ronald W.

AU - Besse, Emmanuelle

AU - Dutreix, Catherine

AU - Fagioli, Franca

AU - Ho, Phoenix A.

AU - Dufour, Carlo

AU - Pieters, Rob

N1 - Funding Information: This study was supported by funding from Novartis Pharmaceuticals Corporation. We thank the patients enrolled in this trial and their families for their participation. We also acknowledge all of the investigators at the study sites that participated in the trial: Erasmus MC–Sophia Children's Hospital, Rotterdam, the Netherlands; Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Hôpital Universitaire Robert-Debré, Paris, France; IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy; Fondazione MBBM, Azienda Ospedaliera San Gerardo, Monza, Italy; Paediatric Onco-Haematology, Stem Cell Transplantation and Cellular Therapy Division, A.O.U. Città della Salute e della Scienza di Torino, Ospedale Infantile Regina Margherita, Torino, Italy; Seattle Children's Hospital, Seattle, WA; Haematology Unit, IRCCS Instituto Giannina Gaslini, Genova, Italy; and Princess Máxima Centre for Paediatric Oncology, Utrecht, the Netherlands. We would also like to thank Katherine Mills-Luján, PhD, CMPP, Amarallys Cintron, PhD, and Pamela Tuttle, PhD, CMPP, of ArticulateScience LLC for medical editorial assistance with this manuscript, which was funded by Novartis Pharmaceuticals Corporation. Funding Information: This study was supported by funding from Novartis Pharmaceuticals Corporation. We thank the patients enrolled in this trial and their families for their participation. We also acknowledge all of the investigators at the study sites that participated in the trial: Erasmus MC–Sophia Children’s Hospital, Rotterdam, the Netherlands; Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Hôpital Universitaire Robert-Debré, Paris, France; IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy; Fondazione MBBM, Azienda Ospedaliera San Gerardo, Monza, Italy; Paediatric Onco-Haematology, Stem Cell Transplantation and Cellular Therapy Division, A.O.U. Cittàdella Salute e della Scienza di Torino, Ospedale Infantile Regina Margherita, Torino, Italy; Seattle Children’s Hospital, Seattle, WA; Haematology Unit, IRCCS Instituto Giannina Gaslini, Genova, Italy; and Princess Máxima Centre for Paediatric Oncology, Utrecht, the Netherlands. We would also like to thank Katherine Mills-Luján, PhD, CMPP, Amarallys Cintron, PhD, and Pamela Tuttle, PhD, CMPP, of ArticulateScience LLC for medical editorial assistance with this manuscript, which was funded by Novartis Pharmaceuticals Corporation.

PY - 2019/5

Y1 - 2019/5

KW - FLT3

KW - acute leukaemia

KW - midostaurin

KW - paediatric

KW - relapsed/refractory

UR - https://www.scopus.com/pages/publications/85053413507

U2 - 10.1111/bjh.15593

DO - 10.1111/bjh.15593

M3 - Letter

C2 - 30203832

AN - SCOPUS:85053413507

SN - 0007-1048

VL - 185

SP - 623

EP - 627

JO - British journal of haematology

JF - British journal of haematology

IS - 3

ER -